{"id":7633,"date":"2026-10-23T08:31:13","date_gmt":"2026-10-23T03:01:13","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-23\/"},"modified":"2026-10-23T18:36:28","modified_gmt":"2026-10-23T13:06:28","slug":"zyduslife-share-price-today-2026-10-23","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-23\/","title":{"rendered":"Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 0.84% | 23 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ZYDUSLIFE<\/strong> \u00b7 23 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,125.50<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-0.84%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,143.50 \/ \u20b91,119.00<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,135.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>13.86 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>23 October 2026 \u00b7 03:00 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Zydus Lifesciences Ltd declined 0.84% on October 23, 2026, closing at \u20b91,125.50 after trading between an intraday low of \u20b91,119.00 and a high of \u20b91,143.50.<\/li>\n<li>Zydus Lifesciences announced that its fully integrated biologics CDMO subsidiary, Zylidac Bio, partnered with Prolific Machines to scale Prolific&#x27;s light-controlled cell line development platform from laboratory setup to GMP production at Zylidac&#x27;s Emeryville facility. The collaboration utilizes optogenetics-enabled technology to improve yields for complex biologics such as multi-specific antibodies without requiring clients to build new manufacturing infrastructure. The partnership establishes an end-to-end pathway spanning early development through commercial-scale supply.<\/li>\n<li>Trading volume was 0.88 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Zydus Lifesciences share price falling on 23 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Zydus Lifesciences Ltd declined 0.84% on October 23, 2026, closing at \u20b91,125.50 after trading between an intraday low of \u20b91,119.00 and a high of \u20b91,143.50.<\/p>\n<p class=\"wt-copy\">The broader market experienced downward pressure during the trading day, with the benchmark Nifty falling 0.90% and the Nifty Pharma sector index dropping 1.04%. Zydus Lifesciences&#x27; mild retreat aligned closely with this broader sector pullback, reflecting prevailing cautious sentiment across pharmaceutical equities.<\/p>\n<p class=\"wt-copy\">Company-specific developments in recent weeks have highlighted ongoing business expansion, including a partnership between Zydus&#x27; subsidiary Zylidac Bio and Prolific Machines to scale next-generation biologics manufacturing on October 21, alongside a USFDA approval for an estradiol and levonorgestrel transdermal system. While these operational updates provide medium-term context, today&#x27;s price action appears primarily driven by general sector consolidation rather than a direct single catalyst.<\/p>\n<p class=\"wt-copy\">13.86 lakh shares traded by 23 October 2026 \u00b7 03:00 PM IST. This compares with a 20-day average daily volume of 15.74 lakh shares (0.88 times). The five-day average daily volume was 10.17 lakh shares. Separately, the NSE report for 22 October 2026 showed 6.94 lakh shares delivered, representing 51.11% of that day\u2019s traded volume. The same report recorded 34,252 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>sector-aligned pullback amid mild volume<\/strong><\/p>\n<p class=\"wt-copy\">Zydus Lifesciences moved down 0.84% in tandem with broader weakness across the Nifty Pharma index and broader markets, while trading volumes remained near normal levels at 0.88 times the 20-day average.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Zylidac Bio and Prolific Machines Biologics Partnership<\/div>\n<div class=\"wt-card-date\">21 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Zydus Lifesciences announced that its fully integrated biologics CDMO subsidiary, Zylidac Bio, partnered with Prolific Machines to scale Prolific&#x27;s light-controlled cell line development platform from laboratory setup to GMP production at Zylidac&#x27;s Emeryville facility. The collaboration utilizes optogenetics-enabled technology to improve yields for complex biologics such as multi-specific antibodies without requiring clients to build new manufacturing infrastructure. The partnership establishes an end-to-end pathway spanning early development through commercial-scale supply.<\/p>\n<p class=\"wt-copy\">It expands Zydus&#x27; advanced biologics manufacturing capabilities and service offerings in the United States without significant new infrastructure outlays.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">USFDA Approval for Transdermal System with CGT Exclusivity<\/div>\n<div class=\"wt-card-date\">21 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company received final USFDA approval for its Abbreviated New Drug Application for the Estradiol and Levonorgestrel Transdermal System, designated as a Competitive Generic Therapy eligible for a 180-day exclusivity period. The product, used to treat menopausal symptoms and prevent postmenopausal osteoporosis, recorded annual sales of approximately USD 45.7 million in the United States according to IQVIA MAT data for August 2026. Manufacturing will take place at the group&#x27;s Moraiya plant in Gujarat.<\/p>\n<p class=\"wt-copy\">It strengthens Zydus&#x27; US specialty generic portfolio with an eligible exclusivity period for a product representing a notable addressable market.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Establishment of Sri Lankan Manufacturing Facility<\/div>\n<div class=\"wt-card-date\">15 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Zydus Sunshine Lifesciences, a proposed joint venture between Zydus Lifesciences and Sunshine Healthcare, signed an agreement with the Board of Investment of Sri Lanka on October 13, 2026, to establish a pharmaceutical manufacturing facility in Horana. The project involves a phased investment exceeding USD 20 million on a four-acre site, with commercial operations slated to begin in 2028. The plant will initially manufacture oral solid dosage forms for the local market.<\/p>\n<p class=\"wt-copy\">This venture supports Zydus&#x27; international footprint expansion and strengthens supply chain resilience in emerging regional markets.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_15102026113006_PressRelease15102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">21 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 21, 2026, titled &quot;Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_21102026182006_PressRelease211020261.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated August 31, 2026, titled &quot;Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_31082026104241_PressRelease31082026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">75.01%<\/div>\n<div class=\"wt-note\">75.01% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">7.05%<\/div>\n<div class=\"wt-note\">6.88% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">18.33%<\/div>\n<div class=\"wt-note\">18.15% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1733872_07102026051035_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Jasodaben Babubhai Patel<\/strong><span class=\"wt-note\">Promoter Group<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>1,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>12 November 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 6.88% on 30 September 2026. This compares with 5.12% on 30 June 2026, a change of +1.76 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 41 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Parag Parikh Flexi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.01 crore shares \u00b7 2.01%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Quant Mutual Fund &#8211; Quant Multi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.48 crore shares \u00b7 1.49%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Kotak Flexicap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.07 crore shares \u00b7 1.07%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1733872_07102026051035_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Macquarie<\/div>\n<div class=\"wt-card-date\">27 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Outperform<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained an Outperform rating following recent developments, keeping the stock in focus.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Citi<\/div>\n<div class=\"wt-card-date\">12 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Sell<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Raised target price while maintaining a Sell rating, questioning valuation levels following quarterly results.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">20 May 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Neutral<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b91,125.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a Neutral rating citing limited upside potential relative to the revised target price.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Upcoming financial results and commentary scheduled for November 2026<\/li>\n<li>Operational progress on the recently approved USFDA transdermal generic launch and CGT exclusivity timeline<\/li>\n<li>Execution updates regarding the Zylidac Bio and Prolific Machines GMP scaling partnership<\/li>\n<li>Delivery volume trends relative to the 51.11% delivery rate observed in the prior cash session<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-22\/\">Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Rising 1.58% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-16\/\">Zydus Lifesciences in Focus After Sri Lanka Plant Agreement; What to Watch | 16 October 2026 \u2014 16 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-15\/\">Zydus Lifesciences in Focus: USFDA Concludes Moraiya Plant Inspection | 15 October 2026 \u2014 15 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/zyduslife\/\">More Zydus Lifesciences news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Zydus Lifesciences company news?<\/h3>\n<p class=\"wt-copy\">Zydus Lifesciences announced that its fully integrated biologics CDMO subsidiary, Zylidac Bio, partnered with Prolific Machines to scale Prolific&#x27;s light-controlled cell line development platform from laboratory setup to GMP production at Zylidac&#x27;s Emeryville facility. The collaboration utilizes optogenetics-enabled technology to improve yields for complex biologics such as multi-specific antibodies without requiring clients to build new manufacturing infrastructure. The partnership establishes an end-to-end pathway spanning early development through commercial-scale supply.<\/p>\n<h3>How strong was Zydus Lifesciences\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">13.86 lakh shares traded, 0.88 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 \u00b7 03:00 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-23\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-23\/\"}, \"headline\": \"Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 0.84% | 23 October 2026\", \"description\": \"Zydus Lifesciences share price fell 0.84% to \u20b91,125.50 today. See why ZYDUSLIFE is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-23T03:01:13Z\", \"dateModified\": \"2026-10-23T18:36:19.051220+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/zyduslife-company-news-2026-10-23.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 21, 2026, titled \\\"Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production\\\".\",\"source\":\"NSE\",\"published\":\"21-Oct-2026 18:27:15\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_21102026182006_PressRelease211020261.pdf\",\"disclosure_text\":\"October 21, 2026 BSE Limited Code: 532321 P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, C\/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Press Release Dear Sir \/ Madam, Please find enclosed a copy of press release dated October 21, 2026, titled \u201cZylidac Bio and Prolific Machines Partner to Scale Prolific\u2019s Next-Generation Biologics Manufacturing Platform to GMP Production\u201d. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors\u2019 at large. Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Zylidac Bio and Prolific Machines Partner to Scale Prolific\u2019s Next-Generation Biologics Manufacturing Platform to GMP Production Zylidac\u2019s Emeryville facility and Prolific Machines will partner to scale Prolific's light-controlled cell line development platform, designed to deliver higher yield, improved control, and enhanced quality for complex biologics, from laboratory development into GMP manufacturing EMERYVILLE, Calif., October 21, 2026 \u2013 Zylidac Bio, a fully integrated biologics CDMO within the Zydus Lifesciences Limited (Zydus) group, and Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced a partnership to scale Prolific's platform from early development through GMP production. Both companies are headquartered in Emeryville in the San Francisco Bay Area. Prolific\u2019s technology uses light to control protein expression in engineered cell lines, enabling substantial gains in productivity and product quality. The platform combines optogenetics- enabled cell lines, illumination systems compatible with standard bioreactors, AI-driven process optimization, and advanced analytics. The technology is particularly useful for difficult-to- express proteins including multi-specific antibodies, fusion proteins, cytokines and other complex modalities. Prolific has reported a record-breaking productivity milestone of 21 g\/L in a 15-day intensified fed-batch CHO run for a monoclonal antibody (mAb) at small scale, along with up to three-fold titer increases for other complex formats. Under the agreement, Zylidac Bio will first complete a tech transfer of Prolific's process at 50- liter scale to reproduce Prolific's results at the Zylidac site. The companies plan to subsequently scale client programs 250 liters, and into GMP manufacturing scale. Prolific's illumination hardware will work seamlessly with Zylidac's existing bioreactors, eliminating the need for customers to build new manufacturing infrastructure. \\\"After demonstrating success at development scale with industry-leading yields across mAbs and difficult-to-express proteins, the next step is scaling the technology to GMP production for clinical and commercial supply,\u201d said Deniz Kent, Ph.D., Chief Executive Officer and Co- Founder of Prolific. \\\"We are very pleased to partner with Zylidac, with a proven team and a great new facility in immediate proximity to our labs in Emeryville. Our science and production teams can work on the same program in the same week, and our clients get a manufacturing partner that already knows the technology.\\\" The partnership creates an end-to-end development and manufacturing pathway for Prolific\u2019s clients, spanning early development through commercial-scale supply. Programs can start with cell line development at Prolific and move seamlessly a short distance to Zylidac for scale-up, drug substance and drug product manufacturing, fill-finish, and packaging. \\\"Our teams visited each other's labs early on, and it was clear the capabilities were highly complementary,\\\" said Steve Lavezoli, Chief Commercial Officer of Zylidac. \\\"Prolific focuses on early-stage cell line development work, while we offer the process development, scale-up and GMP capacity required for later stages, including programs based on new expression technology like Prolific's. We built our Emeryville site to take a molecule from cell line to finished product. We're excited to be the team that takes this technology to production scale.\\\" About Prolific Machines Prolific advances biologics development and manufacturing through optogenetics-enabled cell lines and biomanufacturing solutions. Its platform brings real-time, tunable control of protein expression into standard manufacturing equipment, improving yield, product quality and process control for conventional and complex biologics. The platform is portable across pharma and CDMO facilities and supports programs from early development to scalable, low-COGS manufacturing through flexible service and licensing models. Learn more at prolific- machines.com. About Zylidac Bio Zylidac is a fully integrated biologics manufacturer specializing in monoclonal antibodies, bispecific antibodies, fusion proteins and other complex biologics. From its 83,000-square-foot facility in Emeryville, California, Zylidac takes a molecule from cell line development through drug substance and drug product manufacturing, fill-finish, labeling and secondary packaging. Many team members have worked together for more than 30 years, conducting more than 40 cell bank programs and advancing more than 30 molecules into the clinic. Each Zylidac program runs at one site, under one quality system and one master services agreement, with one team responsible from start to finish. Learn more at zylidacbio.com. About Zydus Lifesciences Limited Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. The group employs 30,000 people worldwide, including 1,500 scientists engaged in research and development. Zydus is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that improve lives. Further information is available at www.zyduslife.com. Media Contacts Zylidac Bio Steve Lavezoli, Chief Commercial Officer Email: slavezoli@zylidacbio.com Phone: 412-360-9185 Prolific Machines Miles Fisher-Pollard Orientation Marketing milesfp@orientation.agency\"},{\"summary\":\"a press release dated August 31, 2026, titled \\\"Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH\\\".\",\"category\":\"Press Release\",\"date\":\"31-Aug-2026 10:43:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_31082026104241_PressRelease31082026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"India's Zydus Life quarterly profit slumps as costs weigh.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated October 21, 2026, titled \\\"Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production\\\".\",\"category\":\"Press Release\",\"date\":\"21-Oct-2026 18:27:15\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_21102026182006_PressRelease211020261.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated August 31, 2026, titled \\\"Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH\\\".\",\"category\":\"Press Release\",\"date\":\"31-Aug-2026 10:43:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_31082026104241_PressRelease31082026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"India's Zydus Life quarterly profit slumps as costs weigh.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated October 21, 2026, titled \\\"Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production\\\".\",\"category\":\"Press Release\",\"date\":\"21-Oct-2026 18:27:15\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_21102026182006_PressRelease211020261.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"insider_activity\":[{\"person\":\"Jasodaben Babubhai Patel\",\"category\":\"Promoter Group\",\"type\":\"Buy\",\"quantity\":\"1000\",\"post_holding\":\"42577\",\"date\":\"12-Nov-2025\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":75.01,\"public_pct\":24.99,\"fii_pct\":7.05,\"dii_pct\":11.28,\"mf_pct\":6.88,\"institutional_pct\":18.33,\"noninst_pct\":6.66,\"mf_scheme_count\":41,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Parag Parikh Flexi Cap Fund\",\"shares\":20092313,\"pct\":2.01},{\"name\":\"Quant Mutual Fund - Quant Multi Cap Fund\",\"shares\":14847839,\"pct\":1.49},{\"name\":\"Kotak Flexicap Fund\",\"shares\":10684809,\"pct\":1.07}],\"period\":\"30-SEP-2026\",\"submission_date\":\"07-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1733872_07102026051035_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":75.01,\"previous_fii_pct\":6.88,\"previous_dii_pct\":11.27,\"previous_mf_pct\":5.12,\"previous_institutional_pct\":18.15,\"previous_mf_scheme_count\":38,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Macquarie\",\"rating\":\"Outperform\",\"target\":null,\"view_summary\":\"Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating.\",\"headline\":\"Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why\",\"published\":\"2026-08-27T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Citi\",\"rating\":\"Sell\",\"target\":null,\"view_summary\":\"Citi, Investec Raise Zydus Life Targets But Keep 'Sell'; Is The Stock Still Too Expensive?\",\"headline\":\"Citi, Investec Raise Zydus Life Targets But Keep 'Sell'; Is The Stock Still Too Expensive?\",\"published\":\"2026-08-12T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Neutral\",\"target\":\"1125\",\"view_summary\":\"Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside \u2014 Check Revised Target Price\",\"headline\":\"Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside \u2014 Check Revised Target Price\",\"published\":\"2026-05-20T07:00:00+00:00\",\"source\":\"NDTV Profit\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences share price fell 0.84% to \u20b91,125.50 today. See why ZYDUSLIFE is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":7632,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 0.84% | 23 October 2026","_witty_meta_description":"Zydus Lifesciences share price fell 0.84% to \u20b91,125.50 today. See why ZYDUSLIFE is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Zydus Lifesciences share price today","_witty_reason_label":"sector-aligned pullback amid mild volume","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[122],"class_list":["post-7633","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-zyduslife"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=7633"}],"version-history":[{"count":3,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7633\/revisions"}],"predecessor-version":[{"id":8258,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7633\/revisions\/8258"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/7632"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=7633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=7633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=7633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}